We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about West Pharmaceutical (WST) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that West Pharmaceutical Services (WST - Free Report) will report quarterly earnings of $2.08 per share in its upcoming release, pointing to a year-over-year increase of 13%. It is anticipated that revenues will amount to $836.8 million, exhibiting an increase of 9.2% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some West Pharmaceutical metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Net Sales- Contract-Manufactured Products' will likely reach $150.69 million. The estimate points to a change of +2.7% from the year-ago quarter.
Analysts expect 'Net Sales- Proprietary Products' to come in at $688.29 million. The estimate indicates a year-over-year change of +11.1%.
The consensus among analysts is that 'Change in Organic Revenue' will reach 9.3%. Compared to the current estimate, the company reported 6.8% in the same quarter of the previous year.
It is projected by analysts that the 'Gross Profit- Proprietary Products' will reach $279.06 million. The estimate compares to the year-ago value of $248.30 million.
The consensus estimate for 'Gross Profit- Contract-Manufactured Products' stands at $24.97 million. Compared to the present estimate, the company reported $25.60 million in the same quarter last year.
Over the past month, West Pharmaceutical shares have recorded returns of +6.9% versus the Zacks S&P 500 composite's -0.6% change. Based on its Zacks Rank #1 (Strong Buy), WST will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Curious about West Pharmaceutical (WST) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Wall Street analysts forecast that West Pharmaceutical Services (WST - Free Report) will report quarterly earnings of $2.08 per share in its upcoming release, pointing to a year-over-year increase of 13%. It is anticipated that revenues will amount to $836.8 million, exhibiting an increase of 9.2% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some West Pharmaceutical metrics that are commonly tracked and projected by analysts on Wall Street.
The combined assessment of analysts suggests that 'Net Sales- Contract-Manufactured Products' will likely reach $150.69 million. The estimate points to a change of +2.7% from the year-ago quarter.
Analysts expect 'Net Sales- Proprietary Products' to come in at $688.29 million. The estimate indicates a year-over-year change of +11.1%.
The consensus among analysts is that 'Change in Organic Revenue' will reach 9.3%. Compared to the current estimate, the company reported 6.8% in the same quarter of the previous year.
It is projected by analysts that the 'Gross Profit- Proprietary Products' will reach $279.06 million. The estimate compares to the year-ago value of $248.30 million.
The consensus estimate for 'Gross Profit- Contract-Manufactured Products' stands at $24.97 million. Compared to the present estimate, the company reported $25.60 million in the same quarter last year.
View all Key Company Metrics for West Pharmaceutical here>>>Over the past month, West Pharmaceutical shares have recorded returns of +6.9% versus the Zacks S&P 500 composite's -0.6% change. Based on its Zacks Rank #1 (Strong Buy), WST will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .